GeNeuro (GNRRF) Stock Price, News & Analysis

Company Overview

GeNeuro SA is a clinical-stage biotechnology company focused on the development of novel therapies that target the human endogenous retrovirus type W (HERV-W) envelope protein. Founded as a spin-off from research at the University of Geneva, the company leverages its proprietary know-how in retroviral biology to address neuroinflammatory and neurodegenerative disorders. Its approach centers on neutralizing factors implicated in chronic inflammation and tissue degeneration within the central nervous system.

The company’s lead candidate, temelimab (formerly GNbAC1), is a monoclonal antibody designed to bind the HERV-W envelope protein and modulate downstream pathogenic pathways. Temelimab has advanced through Phase II clinical trials in progressive forms of multiple sclerosis, demonstrating a favorable safety profile and signals of neuroprotective activity. GeNeuro is also exploring the application of its HERV-W platform in type 1 diabetes and other autoimmune or inflammatory diseases.

GeNeuro maintains its headquarters in Geneva, Switzerland, with additional operations in France and the United States to support global clinical development. The organization has established strategic partnerships to accelerate its late-stage programs and to explore combination approaches with established therapies in neurodegeneration. Its intellectual property portfolio encompasses composition-of-matter patents and methods of use for HERV-based targets.

Supported by an experienced management team and a scientific advisory board with expertise in neurology and immunology, GeNeuro aims to address significant unmet medical needs. The company’s strategic focus remains on advancing temelimab toward registration and expanding its pipeline to include next-generation candidates that harness endogenous retroviral biology for therapeutic benefit.

Key Stats

• Today's Range: $4.55 to $4.55
• 50-Day Range: $4.55 to $4.55
• 52-Week Range: $4.55 to $4.55
• Volume: N/A
• Average Volume: 4,633 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GNRRF Stock Analysis - Frequently Asked Questions

How have GNRRF shares performed this year?

GeNeuro's stock was trading at $4.55 at the beginning of 2025. Since then, GNRRF shares have increased by 0.0% and is now trading at $4.55.

How do I buy shares of GeNeuro?

Shares of GNRRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:GNRRF
• CIK: N/A
• Web: www.geneuro.ch
• Phone: 41 22 552 48 00
• Fax: N/A
• Employees: 17
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A